Moderna, Inc. (MRNA) stock analysis

In our weekly check, Moderna, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 13.

About Moderna, Inc.

Moderna, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as MRNA.

What our checks show for MRNA

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-12

Similar companies

REGN · ARGX · VRTX · ONC · RVMD · GMAB

Questions

What grade does Moderna, Inc. (MRNA) have?

In our weekly check, Moderna, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 13. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of MRNA stock?

This week's biggest flags for Moderna, Inc.: High debt, Weak interest cover, Margins falling. In total 15 of 22 checks show a warning or a red flag.

What does Moderna, Inc. do?

Moderna, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as MRNA.

When does Moderna, Inc. report earnings next?

The next earnings report is expected on 2027-02-12. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis